Member Info for flyingmachine

POSTI, I expect you meant to say Roche and Abbot tests, not Abingdon! Abingdon is the RTC antibody test!

Yes, anyone concerned about when DB may issue news needs to go through the Q&A part again.

no spaces.

replace ********** with v o x markets (so spaces).

The recent Investor presentation is here, if anyone needs to go through it again........

https://api.**********.co.uk/v2/widgets/media/GDR/single?mediaID=5ef0bc14243d7b001b3e038d

If you have already seen this but need to hear the Q&A part again, then this starts about 24 mins in. The slides used in the presentation (with redacting of competitor names) is on the Genedrive website here.....

http://www.genedriveplc.com/company-reports/InvestorPresentationJune2020.pdf

There has been some interesting discussions in the Covid test world about the usability of saliva as a test specimen for Covid tests, particularly for POC settings. I was interested in what Genedrive were planning to do in this area so I asked them the question. I have had a response from them this afternoon........

"The point of care test, genedrive are currently developing, we are indeed exploring alternative specimen types, such as saliva, to ensure ease of use at point of care."

Good to see GDR covering all the potential bases. An accurate POC test using saliva would be great addition to the product range.

Magsy, anyway, great to know you are fully behind Genedrive since you have picked GDR as your only Covid play. It shows tremendous confidence in the future direction of travel. Look out for the de-rampers though, hope you can put your same energy in calling them out, to help protect your sole Covid (GDR) investment of course.

RollingInit, agree, couldn't have picked a better word.....disingenuous.

Any, I am glad Magsy has put all their eggs in the GDR basket, it shows they are fully confident in their pick of Covid stock.

Punter, cannot Magsy answer questions herself without you jumping in, or is Magsy a pal of yours?

Magsy, you are not answering my question? Obviously your focus is on Covid plays and have picked GDR as the best Covid play available. Well done, your choice is good.!

that was for Magsy!

You obviously believe GDR are the best bet in Covid shares at the moment since you only comment on GDR. Are you not in other shares and if you are why do you not make any comments on their boards?

PurleyKing, yes you will have to sell a few other shares if you maxed out your ISA this year. But worth doing it, cheap shares!

Unbelievable (not really!), the Covid-19 cases in USA yesterday were 34720, which is higher than their highest first peak on 10th April (33501). So USA is going backwards in controlling the spread of the disease. So USA could also become a significant market for the new GDR test as soon as FDA EUA approval is given.

Thanks Matt, I have just watched the AS video. Very informative indeed.

ok.... I was looking at the MHRA site.

Matt5521, could you provide the link that specifies MHRA guidelines for a POC antigen test, that you have quoted.

I believe sensitivity is key for a test to determine if you have the active virus. The purpose of the test is to identify the people who have the active virus so that they can be stopped from infecting others, this purpose is best served by having the highest sensitivity possible. To use your example, a test with ridiculous 0% sensitivity will mean that everyone will test negative, so what is the point of the test? A sensitivity of 80% means that 1 in 5 people walk away believing they do not have the virus (a false negative), so go about their business spreading the virus, believing they are clear. 90% sensitivity means the number of false negatives is 1 in 10. In essence, both sensitivity and specificity need to be as high as possible but if the aim is to indentify and control the spread of the virus, sensitivity is most important.

@foreverfalling, regarding your initial question on this thread -"Not sure why Mologic don’t prioritise the (antigen) POC test as that is more valuable one would think", the Mologic news brief on 1st May, last sentence stated "This professional-use RDT sits alongside the other COVID-19 diagnostics Mologic has developed, including lab-based and at-home antibody tests, as well as lab-based, professional use and at-home antigen tests".

The last part of that statement seems to suggest Mologic have already developed (perhaps a version of) the antigen POC test (at beginning of May), so could it be available before the end of this year? They are probably waiting for the MHRA to publish the TPP for these type of tests perhaps.

This has been an interesting thread but in the course of it I haven't seen mention of a couple of keys points:

- Mologic have stated they have already developed (past tense) an at-home antigen tests which ODX will be manufacturing for them. It must be going through validation now.
- This antigen test from Mologic, like any potential Avacta POC antigen test, has to be fully validated especially if it is to be used by an unskilled consumer and must meet MHRA requirements. These requirements are important to satisfy for a POC antigen test if they want it to be a useful mass screening test useable in the UK, but the TPP for these type of tests have not yet been published. I wonder why? The answer to this question you will have to ponder for yourself but is not hard to reach a conclusion once you've researched on the challenge of achieving high levels of sensitivity from an antigen test as opposed to PCR tests.